Key facts
- This page summarizes Alpine ImmunoSciences, L.P.'s Form 4 filing for ALPINE IMMUNE SCIENCES, INC..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Sep 2021, 17:18.
Alpine ImmunoSciences, L.P. - 17 Sep 2021 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 17 Sep 2021
- Net transaction value
- -$3,760,000
- Reporting owner signature
- /s/ Mitchell Gold
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Alpine ImmunoSciences, L.P. filed Form 4 for ALPINE IMMUNE SCIENCES, INC. on 21 Sep 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$3,760,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALPN
transaction
Common Stock
Sale
- Transaction value
- $3,760,000
- Shares
- -400,000
- Change %
- -13%
- Price
- $9.40
- Shares after
- 2,600,980
- Date
- 17 Sep 2021
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Alpine ImmunoSciences, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
These shares were sold in a private transaction to an investor in the Issuer simultaneously with the closing of the Issuer's private placement on September 17, 2021.
Footnote F2
Alpine BioVentures GP, LLC ("ABV LLC") is the general partner of the Reporting Person. Dr. Mitchell Gold and Dr. Jay Venkatesan are the Managing Partners of ABV LLC. Dr. Gold and Dr. Venkatesan are also limited partners of the Reporting Person. By virtue of their positions as Managing Partners of ABV LLC, Dr. Gold and Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by the Reporting Person and as a result may be deemed to have beneficial ownership of such shares. Each of Dr. Gold and Dr. Venkatesan disclaims beneficial ownership of the shares held by the Reporting Person, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, Dr. Gold or Dr. Venkatesan is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.